Aliform develops an innovative surgical tool that enables physicians to treat skin connective tissue defects in a minimally invasive manner. The company's technology aims to help skin surgeons treat a range of connective tissue problems more safely and cost‑effectively while minimizing functional and aesthetic damage. Aliform said it will use the Seed funding to get its first product to market, expand the team, and advance toward clinical stage work. The company announced a $1.7 million Seed round on June 15, 2023 in Dallas, Texas. Brightlands Venture Partners led the round and invested $1.5 million, with participation from a group of business angel investors and US accelerator Health Wildcatters. Aliform positions its tools as easy for surgeons to use and as a way to improve patient outcomes and reduce costs for clinics.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2023